Together, our findings from in vivo experiments demonstrate that loss of Rnf31 and Vps4b sensitize PDA to CTL-mediated killing not only in a cell-autonomous manner, but also in a non-cell-autonomous manner through increasing CTL effector function. The gene discussed is VPS4B; the disease is Patent ductus arteriosus.